Respiratory infections in children up to two years of age on prophylaxis with palivizumab

Monteiro, Ana Isabel M. P.; Bellei, Nancy Cristina J; Sousa, Alessandra Ramos; Santos, Amélia Miyashiro N. dos; Weckx, Lily Yin.
Rev. paul. pediatr ; 32(2): 152-158, 06/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-718516

Documentos relacionados

  1. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
  2. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
  3. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
  4. Rapid antigen detection test for respiratory syncytial virus diagnosis as a diagnostic tool
  5. Society for Maternal-Fetal Medicine Statement: Clinical considerations for the prevention of respiratory syncytial virus disease in infants.
  6. Recent advances in the prevention of respiratory syncytial virus in pediatrics.
  7. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023.
  8. [Respiratory viruses in pediatrics: what's new?].
  9. Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review.
  10. Respiratory syncytial virus and its prophylaxis with palivizumab: exploring nurses' knowledge.